Biora Therapeutics, Inc. (BIOR)
(Delayed Data from NSDQ)
$0.66 USD
+0.03 (5.29%)
Updated Apr 30, 2024 04:00 PM ET
After-Market: $0.66 0.00 (0.70%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMPrice, Consensus and EPS Surprise
BIOR 0.66 +0.03(5.29%)
Will BIOR be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BIOR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BIOR
Is Butterfly Network (BFLY) Outperforming Other Medical Stocks This Year?
Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
BIOR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) Reports Q3 Loss, Lags Revenue Estimates
Other News for BIOR
Biora Therapeutics announces completion of MAD cohorts for BT-600 trial
12 Health Care Stocks Moving In Thursday's After-Market Session
Biora Therapeutics price target lowered by $35 at H.C. Wainwright, here's why
Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations
Biora Therapeutics wins new patent covering Biojet liquid jet delivery technology